Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. lauded results from a clinical study readout. The large magnitude of the positive trend in a deadly cancer is an encouraging sign.

Moderna Comes Alive On Good Performance From Pipeline, Please Try Again

The recommendation is based on clinical data for Moderna's bivalent Omicron-targeting COVID-19 vaccine, mRNA.1273.214 Moderna's bivalent Omicron-targeting COVID-19 vaccines (mRNA.1273.214 (BA.1) & mRNA.1273.222 (BA.4-5)) are approved for use in individuals 12 years of age and older in the European Union Both bivalents have been shown to trigger a superior antibody response compared to a booster dose of mRNA-1273, the Company's prototype vaccine, against Omicron (BA.4-5) in Phase 2/3 clinical trials CAMBRIDGE, MA / ACCESSWIRE / December 16, 2022 / Moderna, Inc.(Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a variation to the marketing authorization (MA) to include a booster dose of Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), at the dose level for children (6-11 years) of 12.5mcg/12.5mcg (0.25 mL) at least three months after the last prior dose of a COVID-19 vaccine. "The recommendation to authorize the use of a booster dose of mRNA-1273.214 in children ages 6-11 is crucial to providing protection against Omicron and the emergence of new variants of concern, which is especially important during the winter period in Europe when respiratory diseases are on the rise," said Stéphane Bancel, Chief Executive Officer of Moderna.

EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna's BA.1 Targeting Bivalent COVID-19 Booster in Children (6-11 Years) In the European Union

Recent results suggest the company's cancer vaccine candidate can succeed where others have failed.

Is Moderna a Good Stock to Buy Right Now?

Moderna stock rallied by close to 20% in Tuesday's trading, after it announced positive results from mid-stage trials for a messenger RNA-based vaccine for skin cancer patients that it is developing with Merck.

Is Moderna Stock A Buy Following Skin Cancer Vaccine Progress?

Data from a mid-stage study showed that Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda reduces the risk of recurrence/death by 44% in melanoma patients.

Moderna (MRNA) Up 20% on Upbeat Data From Cancer Jab Study

Moderna Inc MRNA shares are trading higher by 8.5% to $214.34 on continued upward momentum after the company and Merck announced mRNA-4157/V940 in combination with KEYTRUDA, met the primary efficacy endpoint in the Phase 2b KEYNOTE-942 trial.

Why Moderna Shares Are Rising Again Today - Moderna (NASDAQ:MRNA)

Plotting the next act beyond COVID-19, Moderna CEO Stephane Bancel told Insider his vision for mRNA cancer vaccines.

Moderna's CEO predicts how the biotech's work in cancer vaccines could transform healthcare, starting with your annual physical

Moderna could have a winner with its personalized cancer vaccine. But the company also faces big questions.

Is Moderna Stock a Buy After Its Impressive Cancer Vaccine Results?

Moderna shares rose by almost 20% overnight in the US an experimental cancer vaccine based on its messenger RNA (MRNA) technology boosted survival rates by over 40% in a trial. Shares in pharma companies working on other mRNA-based therapies also jumped on the news with Moderna boss Paul Burton saying the results had “the capacity to be a new paradigm in the treatment of cancer.

Moderna rockets higher as vaccine offers glimpse of 'new paradigm ' in cancer treatment

Moderna, Inc MRNA gapped up 13% to start the trading day on Tuesday and was skyrocketing an additional 12% intraday after announcing that its Merck & Co, Inc MRK partnered cancer vaccine met the primary efficacy endpoint.

Moderna Soars On Cancer Vaccine News: Here's What To Watch Going Forward - Moderna (NASDAQ:MRNA)

Moderna Inc (NASDAQ:MRNA) is up 23.6% at $204.04 at last check, after a mid-stage trial showed the combination of its experimental melanoma vaccine and Merck's (MRK) immunotherapy Keytruda lowered the risk of skin cancer's recurrence or death by 44%.

Encouraging Trial Data Sends Moderna Stock Soaring

Moderna Stock is ripping higher today after a cancer treatment breakthrough. Is Moderna stock a buy now?

Why Moderna Stock Is Popping Over 20% Today

"Now, we are an oncology company," Moderna CEO Stéphane Bancel told Insider.

Moderna just used a personalized vaccine to treat cancer, and it could signal a major breakthrough in how we treat the disease

Merck

Moderna Therapeutics Inc (NASDAQ:MRNA) shares rallied after the biotechnology firm told investors that a trial that combined its investigational cancer vaccine with drug giant Merck & Co Inc (NYSE:MRK)'s immunotherapy Keytruda for patients with stage III/IV melanoma reduced the risk of recurrence or death by 44%. Moderna said the Phase 2b trial of its mRNA cancer vaccine in combination with Keytruda demonstrated a "statistically significant and clinically meaningful improvement" in the primary endpoint of recurrence-free survival versus Keytruda alone.

Moderna shares get a boost from Merck vaccine combo

Oracle

Rivian Automotive

Boeing

Horizon Pharma

So far this week, several stocks have had headline-driven catalysts. We will cover 5 stocks trending in the news.

Trending Today: 5 Stocks in the News

Shares of Moderna Inc (NASDAQ: MRNA) are up nearly 25% on Tuesday after the biotech firm said its experimental vaccine for melanoma showed promising results in a small study.

Moderna stock jumped 25% on a ‘big day for patients'

The pharma giant said combining its cancer vaccine with Merck's Keytruda therapy reduced patients' risk by roughly 44%, versus just Keytruda.

Moderna soars 24% after the drug maker posts upbeat results from cancer vaccine trial

Vaccine-maker Moderna has partnered with the biopharmaceutical company Merck to create an effective treatment for skin cancer

Moderna and Merck team-up to fight melanoma

Moderna's personalized cancer vaccine program just received a big boost.

Why Moderna Stock Is Skyrocketing Today

Pfizer

These companies can continue growing long after the pandemic ends.

2 Pandemic Stocks That Could Make You Richer in 2023 and Beyond

Is Moderna stock a buy after the company offered a promising update for its cancer vaccine? Is MRNA stock a buy right now?

Is Moderna Stock A Buy On A Bullish Update For Its Cancer Vaccine?

First Solar

As markets soar following a healthy inflation report, investors are watching these two companies closely.

2 Nasdaq Stocks Taking Big Strides Forward

Moderna (NASDAQ: MRNA ) stock is rising higher on Tuesday following the release of data from a Phase 2B cancer vaccine clinical trial. Moderna is currently testing its cancer vaccine alongside Merck & Co's (NYSE: MRK ) Keytruda immunotherapy.

Moderna (MRNA) Stock Soars on Cancer Vaccine News

Adding Moderna's experimental messenger RNA-based cancer vaccine to Merck's Keytruda in high-risk melanoma patients reduced the risk of death or recurrence of cancer in a trial.

Moderna Cancer Vaccine Reduces Deaths in Trial

The shot combined with a Merck immunotherapy reduced the risk of relapse in people with skin cancer in a study, Moderna said.

News for Moderna Stock (MRNA)